The market for peptide drugs is a fast-growing and promising innovative segment of the economy. Peptide therapeutics offer advantages over traditional chemical medicines and are being developed by leading pharmaceutical companies in Europe, America and the Asia-Pacific region. The review considers possible options for the development of the global market for peptide therapeutic agents in the next 5-10 years.
Reports and Data (USA), a marketing and consulting company that provides large-scale and customized research reports and consulting services, has released a forecast for the development of the peptide therapeutic market. According to the company's calculations, the turnover of peptide drugs will reach $ 50.60 billion by 2026.
There are objective prerequisites for this development: an increase in the incidence of cancer, a predominance of a sedentary lifestyle leading to metabolic diseases, and the prospects for the healthcare market are key factors contributing to the high average annual growth rate of the market for peptide therapeutic agents during the forecast period.
The global market for peptide therapeutics was estimated at US $ 25.35 billion in 2018 and is expected to reach US $ 50.60 billion by 2026, with a CAGR of ~ 9%. Peptide drugs are used as replacement therapy, supplementing hormonal therapy while decreasing endogenous hormone levels. The history of the medical use of peptides began at the end of the 19th century - the first drug of this kind was the protein hormone insulin for the treatment of patients with diabetes mellitus. More than 60 peptides are currently approved for use in the United States, Europe and Japan. These medicines are used to treat cancer, metabolic disorders, and cardiovascular diseases.
To alter the properties of proteins and increase efficiency, appropriate derivatives are being developed. The attachment of polyethylene glycol (PEG), lipids and proteins is used to increase the half-life of drugs. In recent years, cell-penetrating peptides have been considered ideal simple and non-toxic carriers of active drug agents. They are currently used in cancer therapy due to their high efficacy and fast delivery.
Peptide therapy has specific problems and limitations. Disadvantages include a short plasma life and the difficulty of increasing oral bioavailability. The latter is solved by increasing the stability of the drug and the peptide composition.
Key findings from the report suggest that the peptide therapy market will double in monetary terms from 2018 to 2026. Already, efforts are being made by various companies to develop the market. Thus, Kallyope, a company from the USA, and Novo Nordisk, from Denmark, in June 2018 entered into an agreement to cooperate in the field of research and the discovery of new therapeutic agents for the treatment of obesity and diabetes. North America accounts for the largest share of the peptide market - 38.2% in 2018. Increased market dominance is driven by increased investment in research and development, high incidence of cancer and increased demand for health services. The emergence of new peptide derivatives will also contribute to the rapid growth of the market. The monetary value of solid-phase peptide synthesis is expected to reach USD 22.6 billion by 2026, and hybrid technologies will grow by an average of 8.8%.
With many untapped opportunities, affordable raw material costs and an increase in outsourcing companies, a thriving biotech industry, and increased investment in the R&D sector, Asia Pacific is considered the largest growth market with a CAGR of 10.2% and a turnover of 10 , $ 51 billion in the forecast period. The expiration of patents for blockbuster drugs will drive the generic market, so significant room for growth is expected to emerge soon.
The cancer drugs segment had the largest market share in 2018 - 37.3%. The rise in the number of cancer cases worldwide and the scaling up of treatment are key factors in its predominance.
The metabolic disease segment saw huge market growth of $ 7.05 billion in 2018 and will see significant growth, up 8.9%, in line with forecast due to prevalence of sedentary lifestyles, unhealthy dietary habits and high drug use and alcohol, which leads to an increase in the incidence of such disorders.
In May 2018, biotech company Bicycle Therapeutics introduced a new class of therapeutic agents based on its products, bicyclic peptides (Bicycle), and announced an expansion of its collaboration with Ast